Viscoelastic Memory Foam Patents: Who Leads, Where the Gaps Are 2026
- Filing is far more concentrated in medical and mobility uses than the bedding stereotype suggests. A47C (chairs, sofas & beds) leads at 29.4% of the 3,482 records in scope, but A61F implants and A61M body-fluid devices together account for over a fifth of filings.
- No single company controls the field. The leader holds 219 records and the top 5 combined reach only 15.7% of all 3,482 records — the rest is a long tail of single- and few-filing entrants.
- Filing has cooled from its 2017 peak of 258 but not collapsed. The 2021-to-2024 complete-year window shows a 16% decline, a maturing rather than an abandoned field.
Filing growth compares 2021 (196 records) with 2024 (165) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 3,482 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Viscoelastic memory foam formulation sits at the intersection of comfort materials and clinical device engineering. The dataset behind this page spans 3,482 published records filed between 2015 and mid-2026, captured wherever the claims combine viscoelastic, memory or slow-recovery foam language with tuning concepts such as glass transition tuning, hysteresis loss, gel infusion or pressure distribution. That search string pulls in far more than mattresses: implants, footwear, respiratory-therapy interfaces and patient transport equipment all rely on the same underlying foam chemistry and claim language.
The picture that emerges is a core bedding and seating cluster surrounded by a wide ring of adjacent applications, each with its own assignee base and its own citation pull. Reading the two together — who files the seating claims and who files the interface claims — tells you more about where to search prior art than either alone.
Filing trends and technology composition
Two views of the same 3,482-record dataset: how filing volume has moved year over year, and how records distribute across IPC subclasses. Because a single record can carry several IPC classes, the subclass shares add up to well over 100% — that is expected and reflects genuine claim overlap between bedding, medical and apparel uses.
Filing trend: a 2017 peak followed by a real but partial decline
Filings peaked at 258 in 2017 and the last complete year, 2024, sits at 165 — a 16% drop from 2021's 196. Because publication lags filing by roughly 18 months, the 2025–2026 figures in the chart are still filling in and should not be read as a further fall.
Technology composition: bedding leads, but medical and footwear are substantial
A47C (chairs, sofas & beds) accounts for 29.4% of the 3,482 records, the largest single subclass. A61F implants (12.7%), A43B footwear (11.0%) and A61M body-fluid devices (9.7%) each represent a meaningful independent filing base rather than a spillover from bedding claims.
Shares are the percentage of the 3,482 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Viscoelastic Memory Foam Formulation with Eureka
This page is one run against one query. Ask Eureka your own question about viscoelastic memory foam formulation and every answer comes back with the patent numbers behind it.
Try EurekaA representative early formulation claim
Mattress having reticulated viscoelastic foam (US20050210595A1, Vitafoam)
A foam mattress includes a reticulated, viscoelastic foam that makes up the mattress in whole or in part. The reticulated nature of the viscoelastic foam allows a user to enjoy the benefits of softness and conformability of a viscoelastic foam and also an improved breathability. The foam mattress may include a plurality of zones of foam and/or a plurality of layers of foam, where one of the layers may be reticulated urethane for improved breathability and humidity resistance, as well as heat dissipation.Filed 2005 — illustrates how early this field tied viscoelastic softness claims to breathability and zoned-layer construction, a combination that recurs across later bedding and seating filings.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20090044808A1 | Patient interface | 2,093 |
| 2 | US20140163664A1 | Integrated system for the ballistic and nonballistic infixion and retrieval of implants with or without drug … | 965 |
| 3 | US20190247050A1 | Integrated system for the infixion and retrieval of implants | 450 |
| 4 | US20080060649A1 | Delivery of respiratory therapy | 412 |
| 5 | US20100018534A1 | Delivery of respiratory therapy | 409 |
| 6 | WO2008011682A1 | Delivery of respiratory therapy | 403 |
| 7 | US6093468A | Flexible lightweight protective pad with energy absorbing inserts | 369 |
| 8 | WO2008070929A1 | Delivery of respiratory therapy | 352 |
| 9 | US20100313891A1 | Respiratory mask | 345 |
| 10 | US6413458B1 | Process for forming gelatinous elastomer materials | 307 |
Citation counts favour older, foundational filings inside this searched corpus — treat them as a signal of influence on later filers, not as a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing or freedom-to-operate decision
Three patterns stand out once the assignee ranking, technology composition and receiving-office data are read together.
Leadership is real but not dominant
The leading assignee holds 219 records and the top 5 combined reach 545 records, 15.7% of the 3,482 in scope. That leaves the large majority of filing activity spread across a long tail — useful context before assuming any one company blocks a given formulation route.
US and EPO dominate filing venue choice
United States receives the largest volume of filings at 1,378, with Europe (EPO) at 510 and WIPO (PCT) at 360 behind it. India, Australia and Canada each sit near 150–175, suggesting these are secondary but not negligible filing markets for this technology.
Bedding leads but is not the whole story
A47C (chairs, sofas & beds) is the largest subclass at 29.4% of records, but A61F implants, A43B footwear and A61M devices each carry independent double-digit or near-double-digit shares. Filing here spans consumer comfort and clinical device engineering rather than one industry.
A cooling but not a collapsing field
Filing volume fell from 196 in 2021 to 165 in 2024, a 16% decline over the only span of complete years available. Recent-year assignee momentum data shows several established filers reporting zero or sharply reduced filings in the latest tracked year, consistent with a maturing rather than expanding claim landscape.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to viscoelastic memory foam formulation, with the prior art for and against each one.
Who is filing, and where the claim space is still open
The ranking covers 100 companies counted in records — the full set the data endpoint returns, not a top-50 or top-100 cut. Reading it alongside the co-assignee pairs shows where corporate groups file jointly and where single entities hold ground alone.
One clear leader, no runaway monopoly
The top-ranked assignee holds 219 records, well ahead of the fifth-place holder at 69 and tenth place at 46. That gap suggests a genuine leadership position in filing volume, though 219 of 3,482 records is still a modest fraction of the whole field.
Joint filing is limited and mostly corporate-family driven
Only 10 co-assignee pairs appear in the dataset, and the strongest pairs look like intra-group filings — a chemicals parent with its subsidiary, or a sleep-therapy company with its regional affiliate — rather than cross-company R&D alliances.
Several established filers have gone quiet in the latest year
Recent-year momentum data shows multiple top-ranked assignees, including sleep-therapy, footwear and materials companies, recording zero filings in the latest tracked year, and one recording a 64% year-on-year drop. This does not necessarily mean exit — publication lag means the newest filings from these firms may not yet be visible.
| Assignee | Recent year | YoY |
|---|---|---|
| Acushnet Company | 4 | -64% |
| ResMed Ltd | 0 | -100% |
| Nike Innovate C.V. | 0 | — |
| Tempur World LLC | 0 | — |
| Smith & Nephew plc | 0 | — |
| Dreamwell Ltd | 0 | — |
| Natural Fiber Welding Inc | 0 | — |
| 3M Innovative Properties Company | 0 | — |
Where to take this analysis
The dataset points to two practical next steps: narrowing prior art search inside the under-claimed branches, and watching whether the 2024 decline continues once 2025–2026 filings finish publishing.
Run a freedom-to-operate check on a specific formulation
Use the gate chips above as a starting list of sub-areas with thinner claim density, then pull the full claim text of the nearest-cited records before drafting.
Explore in Eureka →Track assignee momentum past the publication lag
Several leading filers show zero recent-year activity, which may reverse once 2025–2026 filings complete publication. Re-check this in 12–18 months.
Set up monitoring in Eureka →Common questions about this landscape
The leading assignee in this dataset holds 219 of the 3,482 records in scope, with the fifth-ranked assignee at 69 and the tenth at 46. The top 5 combined account for 15.7% of all records and the top 10 for 23.0%, which means the field is led but not dominated by any single company. The remaining three-quarters of filings are spread across a long tail of companies with smaller or single-filing footprints, so a freedom-to-operate search needs to look well beyond the top names.
Filing peaked in 2017 at 258 records and fell to 165 by 2024, a 16% decline measured over the 2021-to-2024 span of complete years. That is a real cooling, not a collapse. Because patent publication lags filing by roughly 18 months, the lower figures shown for 2025 and 2026 in raw trend data are still filling in and should not be read as an accelerating drop.
Bedding and seating (IPC class A47C) is the largest single category at 29.4% of the 3,482 records in scope, but the field is broader than mattresses. Implants and prostheses (A61F) cover 12.7%, footwear (A43B) 11.0%, and devices for body fluids such as respiratory interfaces (A61M) 9.7%. Because records often carry multiple IPC classes, these categories overlap rather than sum to a clean total, reflecting genuine cross-application use of the same foam chemistry.
The United States receives the largest share of filings among tracked receiving offices at 1,378, followed by the European Patent Office at 510 and the WIPO PCT route at 360. India, Australia and Canada each sit in the 150–175 range, indicating these are meaningful but secondary filing venues rather than primary markets for this technology.
US20050210595A1, assigned to Vitafoam and filed in 2005, claims a mattress built from reticulated viscoelastic foam, combining the conformability of viscoelastic foam with improved breathability through an open-cell reticulated structure. It also covers zoned and multi-layer foam constructions, including a reticulated urethane layer specifically for breathability, humidity resistance and heat dissipation. Anyone drafting a new zoned or breathable viscoelastic mattress claim should check this record's claim scope directly, since it is one of the most-cited early filings combining these specific elements.
Yes, based on relative claim density: sub-areas such as zoned gel-infusion layering, hysteresis-loss control specifically for footwear midsoles, and glass-transition tuning applied to garment padding show thinner filing activity than the core bedding and medical clusters. This does not guarantee an area is unclaimed, only that fewer records in this dataset target it directly, so it is a reasonable starting point for a narrower prior-art search rather than a guarantee of open claim space.
Research Viscoelastic Memory Foam Formulation in depth with Eureka
Go past this page: query the whole viscoelastic memory foam formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.